Shuttle Pharma Finalizes Highly Dilutive $3.5M Offering at Deep Discount, Issuing 7M Shares
SHPH is trading near its 52-week low of $0.8 (15% above the low) on light trading volume (0.1× avg).
Summary
Shuttle Pharmaceuticals finalized a public offering to raise $3.5 million by selling 2.24 million common shares and 4.76 million pre-funded warrants at a significant discount, leading to substantial potential dilution for existing shareholders.
Key Events · Financing and Capital Events · SHPH
-
Offering Finalized and Priced
The company is offering 2,238,800 shares of common stock at $0.50 per share and pre-funded warrants to purchase up to 4,761,200 shares at $0.499 per warrant, with an exercise price of $0.001 per share. Total gross proceeds are approximately $3.5 million.
-
Deep Discount Pricing
The offering price of $0.50 per common share is a significant discount compared to the closing price of $0.87 on March 5, 2026, and the current market price of $0.917.
-
Substantial Potential Dilution
The offering could result in the issuance of up to 7,000,000 new shares (common stock plus shares from warrant exercise), representing over 200% of the 3,352,490 shares outstanding as of March 5, 2026.
-
Critical Capital Raise for Distressed Company
This financing is crucial for the company, which reported a working capital deficit of $0.7-$0.8 million as of December 31, 2025, and has a going concern warning from its auditors.
Analysis · SHPH · Life Sciences
Shuttle Pharmaceuticals has finalized the terms of its public offering, which was previously announced. The company is raising approximately $3.5 million by selling 2.24 million shares of common stock at $0.50 per share and 4.76 million pre-funded warrants at $0.499 each. This pricing represents a substantial discount to the stock's closing price of $0.87 on March 5, 2026, and today's price of $0.917. The offering introduces a significant number of new securities, with the potential issuance of 7 million shares (common stock plus shares from warrant exercise) compared to 3.35 million shares currently outstanding, indicating over 200% potential dilution. This capital raise is critical for the company, which reported a working capital deficit and has a going concern warning from its auditors. The proceeds are earmarked for marketing expenses and general working capital, following a prior $3.45 million spend on investor relations in 2025. While providing necessary capital, the terms of this offering are highly unfavorable for existing shareholders due to the deep discount and massive dilutive impact.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHPH was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.80 to $14.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.